LCD L39553: Radiation Therapies — Palmetto GBA
Policy LCD-L39553 · Oncology
New LCD may impact radiation therapy billing practices.
Code intelligence
C50.9 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code C50.9.
Elevated code riskView ICD-10 detail
Signal breakdown
6 shown · 6 total in platform
Risk: Elevated
0
Critical
0%
3
High
50%
3
Routine
50%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
High
Proposed LCD DL40226: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer — CGS
Policy LCD-DL40226 · Oncology
Proposed LCD on targeted molecular tests may affect oncology billing.
LCD L37794: MolDX: Breast Cancer Index® (BCI) Gene Expression Test — Palmetto GBA
Policy LCD-L37794 · Oncology
New BCI test impacts billing effective July 2025.
LCD L36658: Proton Beam Therapy — CGS
Policy LCD-L36658 · Oncology
Proton Beam Therapy requires billing team review-2025.
LCD L36380: MolDX: Breast Cancer Assay: Prosigna® — Noridian
Policy LCD-L36380 · Oncology
New LCD for Prosigna® requires billing team review.
Proposed LCD DL40246: MolDX: Biomarker Testing for Risk Stratification in DCIS — CGS
Policy LCD-DL40246 · Oncology
New LCD could enhance coverage for DCIS biomarker tests.
Audit documentation
Building an audit file that includes C50.9?
The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Oncology audit pack — $349One-time purchase · not a subscription